Literature DB >> 19414991

Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course.

Patrick R Harrington1, Gretja Schnell, Scott L Letendre, Kimberly Ritola, Kevin Robertson, Colin Hall, Christina L Burch, Cassandra B Jabara, Dominic T Moore, Ronald J Ellis, Richard W Price, Ronald Swanstrom.   

Abstract

OBJECTIVES: To characterize HIV-1 env compartmentalization between cerebrospinal fluid (CSF) and peripheral blood plasma over all stages of the HIV-1 disease course, and to determine the relationship between the extent of CSF HIV-1 env compartmentalization and clinical neurologic disease status.
DESIGN: Paired blood plasma and CSF specimens were collected from 66 HIV-infected patients cross-sectionally representing all major clinical stages relating to HIV-associated neurologic disease, including primary infection, asymptomatic chronic infection, chronic infection with minor global impairment, and immune deficiency with HIV-associated dementia.
METHODS: Heteroduplex tracking assays and bulk sequence analysis targeting the V1/V2, C2-V3, and V4/V5 regions of env were performed to characterize the genetic makeup of complex HIV-1 populations in the cross-sectional blood plasma and CSF specimens. The levels of blood plasma/CSF env compartmentalization were quantified and compared across the different clinical stages of HIV-1 neurologic disease.
RESULTS: Blood plasma/CSF env compartmentalization levels varied considerably by disease stage and were generally consistent across all three regions of env characterized. Little or no compartmentalization was observed in non-impaired individuals with primary HIV-1 infection. Compartmentalization levels were elevated in chronically infected patients, but were not significantly different between mildly impaired and non-impaired patients. Patients with HIV-associated dementia showed significantly greater blood plasma/CSF env compartmentalization relative to other groups.
CONCLUSION: : Increased CSF compartmentalization of the HIV-1 env gene, which may reflect independent HIV-1 replication and evolution within the central nervous system, is specifically associated with HIV-associated dementia and not the less severe forms of HIV-1 neurologic disease.

Entities:  

Mesh:

Year:  2009        PMID: 19414991      PMCID: PMC3089803          DOI: 10.1097/QAD.0b013e3283299129

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  33 in total

Review 1.  HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era.

Authors:  Olivier Lambotte; Kumaran Deiva; Marc Tardieu
Journal:  Brain Pathol       Date:  2003-01       Impact factor: 6.508

2.  Comparison of human immunodeficiency virus type 1 RNA sequence heterogeneity in cerebrospinal fluid and plasma.

Authors:  Y W Tang; J T Huong; R M Lloyd; P Spearman; D W Haas
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

Review 3.  Antiretroviral treatment of central nervous system HIV-1 infection: a review.

Authors:  M Gisslén; L Hagberg
Journal:  HIV Med       Date:  2001-04       Impact factor: 3.180

4.  HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir.

Authors:  E R Lanier; G Sturge; D McClernon; S Brown; M Halman; N Sacktor; J McArthur; J H Atkinson; D Clifford; R W Price; D Simpson; G Torres; J Catalan; K Marder; C Power; C Hall; C Romero; B Brew
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

5.  Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.

Authors:  R Shankarappa; J B Margolick; S J Gange; A G Rodrigo; D Upchurch; H Farzadegan; P Gupta; C R Rinaldo; G H Learn; X He; X L Huang; J I Mullins
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources.

Authors:  R J Ellis; A C Gamst; E Capparelli; S A Spector; K Hsia; T Wolfson; I Abramson; I Grant; J A McCutchan
Journal:  Neurology       Date:  2000-02-22       Impact factor: 9.910

7.  HIV-associated cognitive impairment before and after the advent of combination therapy.

Authors:  Ned Sacktor; Michael P McDermott; Karen Marder; Giovanni Schifitto; Ola A Selnes; Justin C McArthur; Yaakov Stern; Steve Albert; Donna Palumbo; Karl Kieburtz; Joy A De Marcaida; Bruce Cohen; Leon Epstein
Journal:  J Neurovirol       Date:  2002-04       Impact factor: 2.643

8.  Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.

Authors:  Christian Eggers; Kurt Hertogs; Hans-Jörg Stürenburg; Jan van Lunzen; Hans-Jürgen Stellbrink
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

Review 9.  The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy.

Authors:  Ned Sacktor
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

10.  Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection.

Authors:  Kathryn M Kitrinos; Noah G Hoffman; Julie A E Nelson; Ronald Swanstrom
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more
  70 in total

Review 1.  Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction.

Authors:  K Grovit-Ferbas; M E Harris-White
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

2.  Individuals with HIV-1 Subtype C Infection and Cryptococcal Meningitis Exhibit Viral Genetic Intermixing of HIV-1 Between Plasma and Cerebrospinal Fluid and a High Prevalence of CXCR4-Using Variants.

Authors:  Katlego Sojane; Richard T Kangethe; Christina C Chang; Mahomed-Yunus S Moosa; Sharon R Lewin; Martyn A French; Thumbi Ndung'u
Journal:  AIDS Res Hum Retroviruses       Date:  2018-05-23       Impact factor: 2.205

3.  Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.

Authors:  Michael J Peluso; Serena Spudich
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

Review 4.  Translational challenges in targeting latent HIV infection and the CNS reservoir problem.

Authors:  Carolina Garrido; David M Margolis
Journal:  J Neurovirol       Date:  2014-07-25       Impact factor: 2.643

Review 5.  Neurocognitive impact of antiretroviral treatment: thinking long-term.

Authors:  Megan E McPhail; Kevin R Robertson
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

6.  Discordant patterns of tissue-specific genetic characteristics in the HIV-1 env gene from HIV-associated neurocognitive disorder (HAND) and non-HAND patients.

Authors:  Yabo Ouyang; Lifeng Liu; Yulin Zhang; Lin Yuan; Zhiying Liu; Sufang Yang; Feili Wei; Luxin Qiao; Dexi Chen
Journal:  J Neurovirol       Date:  2014-04-23       Impact factor: 2.643

Review 7.  Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.

Authors:  Maria M Bednar; Christa Buckheit Sturdevant; Lauren A Tompkins; Kathryn Twigg Arrildt; Elena Dukhovlinova; Laura P Kincer; Ronald Swanstrom
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

8.  Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection.

Authors:  Gretja Schnell; Richard W Price; Ronald Swanstrom; Serena Spudich
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

9.  The perils of PCR: can we accurately 'correct' antimalarial trials?

Authors:  Jonathan J Juliano; Nahla Gadalla; Colin J Sutherland; Steven R Meshnick
Journal:  Trends Parasitol       Date:  2010-01-18

Review 10.  Interplay between Wnt/β-catenin signaling and HIV: virologic and biologic consequences in the CNS.

Authors:  Lena Al-Harthi
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-13       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.